Skip to main content
Clinical Trials/CTRI/2020/08/027020
CTRI/2020/08/027020
Completed
未知

Safety In-Use Study to Assess the Cutaneous Tolerance of Tear Free Baby body wash and Shampoo in Healthy Babies of 0 to 36 Months of Age.

Azafran Innovacion ltd0 sites38 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Azafran Innovacion ltd
Enrollment
38
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
Azafran Innovacion ltd

Eligibility Criteria

Inclusion Criteria

  • 1 Babies in the age group of 0 (including new born full term babies Day 1\) to 36 months (inclusive of both genders) at the time of consent
  • 2 Babies general in good health as determined from a recent medical history
  • 3 Babies mother or legal representative preferably mother willing to give a voluntary written parental informed consent and agree to come for regular follow up
  • 4 Babies mother or legal representative preferably mother willing to abide by and comply with the study protocol
  • 5 Babies should not participate in any other clinical study during participation in the current study

Exclusion Criteria

  • 1 Subjectââ?¬•s mother or legal caretaker not willing to stop the use of other baby body milk or lotion or cream or any other baby face or body moisturizing product during the study period
  • 2 Chronic illness which may influence the cutaneous state
  • 3 Subject on any systemic medication
  • 4 Subject with birth defects and anomalies
  • 5 Subject participating in a similar clinical study currently or during the previous 30 days
  • 6 Any subject in the Investigators opinion not considered suitable for enrollment
  • 7 A known history or present condition of allergic response to any other concern that may require medical attention
  • 8 Babies with medical history (past present) of significant dermatological diseases or conditions such as atopy psoriasis vitiligo or other conditions known to alter skin appearance or physiologic response (eg.porphyria) chronic urticaria or sunburn rashes

Outcomes

Primary Outcomes

Not specified

Similar Trials